$1.98
+0.11 (+5.88%)
Open$1.87
Previous Close$1.87
Day High$2.07
Day Low$1.87
52W High$44.73
52W Low$27.64
Volume—
Avg Volume535.4K
Market Cap7.53M
P/E Ratio54.61
EPS$0.59
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,865.7% upside
Current
$1.98
$1.98
Target
$38.92
$38.92
$24.59
$38.92 avg
$51.00
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 555.8K | 518.1K | 501.1K |
| Net Income | 113.5K | 116.0K | 100.3K |
| Profit Margin | 20.4% | 22.4% | 20.0% |
| EBITDA | 245.4K | 221.0K | 210.9K |
| Free Cash Flow | 70.8K | 77.8K | 93.1K |
| Rev Growth | -5.3% | +6.0% | -5.8% |
| Debt/Equity | 0.43 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |